Michelle Glazer Zucker, DO
Family Medicine · Madison Heights, MINPI 1487638771
Payments from drug & device makers
Across 654 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Lilly USA, LLC$1K
- GSK$1K
- Pfizer$777
- AbbVie$723
- plus $3K from 25 others
What the payments were for
- Food & beverage$9,872100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 119 | $1,816 |
| AstraZeneca | 83 | $1,561 |
| Lilly USA, LLC | 79 | $1,112 |
| GSK | 79 | $1,048 |
| Pfizer | 54 | $777 |
| AbbVie(2 entities) | 44 | $723 |
| Boehringer Ingelheim | 33 | $611 |
| Astellas Pharma US Inc | 17 | $299 |
| Abbott | 12 | $266 |
| Amgen | 15 | $245 |
| Merck | 21 | $192 |
| Johnson & Johnson | 32 | $135 |
| Amarin Pharma, Inc. | 10 | $131 |
| Bausch Health US, LLC | 8 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $125 |
| Mylan Specialty L.p. | 5 | $109 |
| Dexcom, Inc. | 5 | $90 |
| Axsome Therapeutics, Inc. | 4 | $82 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| Lundbeck LLC | 2 | $46 |
| Bayer | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $31 |
| Novartis | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Pulmonx Corporation | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,881 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 123 | $135,857 |
| JardianceEmpagliflozin | 51 | $78,774 |
| OzempicSemaglutide | 73 | $78,549 |
| EliquisApixaban | 43 | $47,176 |
| RybelsusSemaglutide | 18 | $35,055 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $34,356 |
| LinzessLinaclotide | 48 | $32,647 |
| JanuviaSitagliptin Phosphate | 17 | $23,730 |
| XareltoRivaroxaban | 15 | $19,809 |
| RexultiBrexpiprazole | 11 | $18,650 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $17,827 |
| FarxigaDapagliflozin Propanediol | 22 | $15,975 |
| TrintellixVortioxetine Hydrobromide | 31 | $15,722 |
| TrulicityDulaglutide | 11 | $14,280 |
| VeozahFezolinetant | 23 | $11,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,112 | $150,137134 claims |
| Novo NordiskOzempic, Rybelsus | $1,816 | $113,60491 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $611 | $87,59870 claims |
| PfizerEliquis | $777 | $47,17643 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,048 | $41,93463 claims |
| AbbVieLinzess, Synthroid | $723 | $34,19068 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $1,561 | $33,80154 claims |
| MerckJanuvia | $192 | $23,73017 claims |
| Johnson & JohnsonXarelto | $135 | $19,80915 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $49 | $15,72231 claims |
| Astellas Pharma US IncVeozah | $299 | $11,95823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Madison Heights
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.